Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

International journal of laboratory hematology - 1 Jun 2018

Lewandowski K, Gniot M, Wojtaszewska M, Kanduła Z, Becht R, Paczkowska E, Mędraś E, Wasilewska E, Iwoła M

Abstract excerpt

INTRODUCTION: There are 7 designated conditions under the category of myeloproliferative neoplasms (MPN), including chronic myelogenous leukemia (CML) and classical MPN, that is, polycythemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF). Recently, reports about Philadelphia and JAK2 V617F-positive MPN cases have been described in literature. The coexistence of different molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Splenomegaly

Share to Thrombocytosis

Source

Identifiers

PMID: 29508552
DOI: 10.1111/ijlh.12798

Genes

JAK2
CALR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.PMID 29508552Read ↗

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?Semantic proximity Read ↗

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.Semantic proximity Read ↗

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Semantic proximity Read ↗

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL.Semantic proximity Read ↗

Current approaches to challenging scenarios in myeloproliferative neoplasms.Semantic proximity Read ↗

CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.Semantic proximity Read ↗

[Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].Semantic proximity Read ↗

A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations.Semantic proximity Read ↗

In Patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course?Semantic proximity Read ↗

JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.Semantic proximity Read ↗

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.